From: Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Agents | Diseases | Phase | NCT |
---|---|---|---|
ACP-196 Dexamethasone | MM | Phase 1 | NCT02211014 |
ACP-196 | ABC DLBCL | Phase 1 | NCT02112526 |
ACP-196 Rituximab (IV) | FL | Phase 1 | NCT02180711 |
ACP-196 Obinutuzumab | CLL, SLL, PLL | Phase 1 | NCT02296918 |
ACP-196 ACP-319 | CLL | Phase 1 | NCT02157324 |
ACP-196 ACP-319 | NHL, MM, B-All | Phase 1/2 | NCT02328014 |
ACP-196 | WM | Phase 1/2 | NCT02180724 |
ACP-196 | CLL, SLL, RS, PLL | Phase 1/2 | NCT02029443 |
ACP-196 Pembrolizumab | NHL, MM, HL, CLL, RS, WM, Myelofibrosis | Phase 1/2 | NCT02362035 |
ACP-196 | CLL, SLL | Phase 2 | NCT02337829 |
ACP-196 | MCL | Phase 2 | NCT02213926 |
ACP-196 Obinutuzumab Chlorambucil | CLL | Phase 3 | NCT02475681 |
ACP-196 Ibrutinib | CLL | Phase 3 | NCT02477696 |